STK32A and non-small cell lung carcinoma: Our loss-and-gain functional assays delivered that overexpression of STK32A resulted in potentiated NSCLC cell viability, migration as well as invasion, in addition to enhanced NF-κB p65 phosphorylation, whilst repressed cell apoptosis.